Accepted for/Published in: JMIR Research Protocols
Date Submitted: May 19, 2021
Date Accepted: May 26, 2021
Optimizing oral targeted anticancer therapies (OpTAT) study for patients with solid cancer: protocol for a randomized controlled medication adherence program along with a systematic collection and modeling of pharmacokinetic and pharmacodynamic data
ABSTRACT
Background:
The strengthening or substitution of intravenous cytotoxic chemotherapy cycles by oral targeted anticancer therapies, such as protein kinase inhibitors (PKIs), has provided impressive clinical benefits and autonomy as well as a better quality of life for cancer patients. Despite these advances, adverse event management at home and medication adherence remain a challenge. In addition, PKI plasma concentrations vary significantly among cancer patients receiving the same dosage, which could explain part of the observed variability in the therapeutic response.
Objective:
The aim of the Optimizing oral targeted anticancer therapies (OpTAT) study is to optimize and individualize targeted anticancer treatments to improve patient care and self-monitoring through an interprofessional medication adherence program (IMAP) combined with monitoring PKI plasma concentrations.
Methods:
The OpTAT study has two parts: 1) a 1:1 randomized medication adherence program, where the intervention consists of regular motivational interviewing sessions between the patient and the pharmacist, along with the delivery of PKI in electronic monitors (EM); and 2) a systematic collection of blood samples and clinical and biological data for combined pharmacokinetic and pharmacodynamic analysis. Based on the EM data, the implementation will be described using a generalized estimating equation (GEE) models. The persistence of the use of PKI will be represented with a Kaplan-Meier survival curve. Longitudinal adherence is defined as the product of persistence and implementation. The PKI pharmacokinetics will be studied using a population approach. The relationship between drug exposure and efficacy outcomes will be explored using Cox regression analysis of progression-free survival. The relationship between drug exposure and toxicity will be analyzed by a pharmacokinetic-pharmacodynamic model and by logistic regression analysis. Receiver operating characteristic (ROC) analyses will be applied to evaluate the best exposure threshold associated with clinical benefits.
Results:
The first patient was included in May 2015. Since then, 259 patients have participated in at least one part of the study: 247 patients gave at least one blood sample, and 130 participated in the adherence study. Data collection is in process, and the final data analysis is planned to be performed in 2022.
Conclusions:
The OpTAT study will inform us about the effectiveness of the IMAP program in patients with solid cancers treated with PKIs. It will also shed light on PKI pharmacokinetic-pharmacodynamic properties, with the aim of learning how to adapt the PKI dosage at the individual patient level to increase PKI clinical suitability. The IMAP program will enable interprofessional teams to learn about patients’ needs and to consider their concerns about their PKI self-management, considering the patient as an active partner. Clinical Trial: Clinicaltrials.gov NCT04484064
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.